Shares of Clearside Biomedical Inc (NASDAQ:CLSD) have earned a consensus broker rating score of 1.25 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation and three have issued a strong buy recommendation on the company.

Brokerages have set a twelve-month consensus target price of $19.00 for the company and are expecting that the company will post ($0.45) EPS for the current quarter, according to Zacks. Zacks has also given Clearside Biomedical an industry rank of 92 out of 265 based on the ratings given to related companies.

A number of analysts have weighed in on the company. Wedbush assumed coverage on Clearside Biomedical in a research note on Monday, June 27th. They issued an “outperform” rating and a $28.00 target price on the stock. Zacks Investment Research upgraded Clearside Biomedical from a “hold” rating to a “buy” rating and set a $7.75 price target on the stock in a research note on Friday, August 26th. Needham & Company LLC began coverage on Clearside Biomedical in a research note on Tuesday, June 28th. They set a “buy” rating and a $16.00 price target on the stock. Stifel Nicolaus began coverage on Clearside Biomedical in a research note on Monday, June 27th. They set a “buy” rating and a $13.00 price target on the stock. Finally, Cowen and Company began coverage on Clearside Biomedical in a research note on Monday, June 27th. They set an “outperform” rating on the stock.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/brokerages-anticipate-clearside-biomedical-inc-nasdaqclsd-to-post-0-45-earnings-per-share.html

Several institutional investors have recently made changes to their positions in the stock. AWM Investment Company Inc. purchased a new position in shares of Clearside Biomedical during the second quarter valued at approximately $350,000. Iguana Healthcare Management LLC bought a new position in Clearside Biomedical during the second quarter valued at about $526,000. Marshall Wace LLP bought a new position in Clearside Biomedical during the second quarter valued at about $1,122,000. Finally, Perceptive Advisors LLC bought a new position in Clearside Biomedical during the second quarter valued at about $4,450,000.

Shares of Clearside Biomedical (NASDAQ:CLSD) traded up 3.9100% during trading on Tuesday, reaching $10.8482. The company’s stock had a trading volume of 206,469 shares. Clearside Biomedical has a 12-month low of $5.65 and a 12-month high of $12.00. The stock’s market capitalization is $222.88 million. The firm’s 50-day moving average is $7.38 and its 200-day moving average is $7.07.

Clearside Biomedical (NASDAQ:CLSD) last released its earnings results on Thursday, August 11th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by $0.30. Equities analysts expect that Clearside Biomedical will post ($2.10) earnings per share for the current year.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc is a late-stage clinical biopharmaceutical company. The Company is developing drug therapies to treat blinding diseases of the eye. The Company’s product candidates are focused on diseases affecting the retina and choroid, especially diseases associated with macular edema, and are injected into the suprachoroidal space (SCS) adjacent to the choroid, using its SCS Microinjector.

5 Day Chart for NASDAQ:CLSD

Get a free copy of the Zacks research report on Clearside Biomedical (CLSD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Clearside Biomedical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc and related companies with MarketBeat.com's FREE daily email newsletter.